Effect of previous therapies on treatment retention and satisfaction in patients randomized to fingolimod or injectable disease-modifying therapies in PREFERMS

被引：0
|
作者：
Thomas, Florian P. [1 ,2 ]
Hunter, Samuel F. [3 ]
Meng, Xiangyi [4 ]
Schofield, Lesley [4 ]
Kolodny, Scott [4 ]
Tenenbaum, Nadia [4 ]
Cree, Bruce A. C. [5 ]
机构：
[1] Seton Hall Hackensack Meridian Sch Med, S Orange, NJ USA
[2] Hackensack Univ, Med Ctr, S Orange, NJ USA
[3] Adv Neurosci Inst, Franklin, TN USA
[4] Novartis Pharmaceut Corp, E Hanover, NJ USA
[5] UCSF Weill Inst Neurosci, San Francisco, CA USA
来源：
NEUROLOGY | 2018年 / 90卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1.357
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain
    Carole Dembek
    Leigh Ann White
    Jayson Quach
    Andrea Szkurhan
    Nazia Rashid
    M. R. Blasco
    [J]. The European Journal of Health Economics, 2014, 15 : 353 - 362
  • [22] Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain
    Dembek, Carole
    White, Leigh Ann
    Quach, Jayson
    Szkurhan, Andrea
    Rashid, Nazia
    Blasco, M. R.
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2014, 15 (04): : 353 - 362
  • [23] Patient response to new disease-modifying therapies: results of a questionnaire study in RRMS patients receiving self-injected disease-modifying therapies
    Caon, C.
    Memon, A.
    Perumal, J.
    Khan, O.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S472 - S472
  • [24] Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies
    Grebenciucova, Elena
    Pruitt, Amy
    [J]. CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2017, 17 (11)
  • [25] Patient Response to New Disease-Modifying Therapies: Results of a Questionnaire Study in RRMS Patients Receiving Self-Injected Disease-Modifying Therapies
    Caon, Christina
    Memon, Anza
    Perumal, Jai
    Khan, Omar
    [J]. NEUROLOGY, 2011, 76 (09) : A72 - A72
  • [26] The benefits of fingolimod in multiple sclerosis patients experiencing persistent disease activity despite previous treatment with disease-modifying therapies: results from the phase III TRANSFORMS study and its extension
    Cohen, J.
    Francis, G.
    Meinel, M.
    Eckert, B.
    [J]. JOURNAL OF NEUROLOGY, 2011, 258 : 258 - 258
  • [27] Impact of disease-modifying therapies on myostatin levels in SMA patients
    Mackels, L.
    Mariot, V.
    Servais, L.
    Dumonceaux, J.
    [J]. NEUROMUSCULAR DISORDERS, 2022, 32 : S58 - S58
  • [28] Patients' preferences and willingness-to-pay for disease-modifying therapies
    Frost, Natasha
    Freeman, Jerome
    Brixner, Diana
    Mort, Jane
    Clem, James
    Ngorsuraches, Surachat
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 35 : 55 - 60
  • [29] Persistence to oral disease-modifying therapies in multiple sclerosis patients
    Simona Lattanzi
    Maura Danni
    Ruja Taffi
    Raffaella Cerqua
    Giulia Carlini
    Alessandra Pulcini
    Leandro Provinciali
    Mauro Silvestrini
    [J]. Journal of Neurology, 2017, 264 : 2325 - 2329
  • [30] Disease-modifying therapies should be stopped in NMOSD patients in remission - No
    Rotstein, Dalia L.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (09) : 1218 - 1220
12345